Prevention and management of adverse events related to regorafenib

Regorafenib is an oral multikinase inhibitor that has shown antitumor activity in a range of solid tumors. Based on data from phase III clinical trials, regorafenib is indicated for the treatment of adult patients with metastatic colorectal cancer who have previously been treated with, or are not co...

Descripción completa

Detalles Bibliográficos
Autores principales: De Wit, Mieke, Boers-Doets, Christine B., Saettini, Alessandra, Vermeersch, Kristina, de Juan, Carmen Roncero, Ouwerkerk, Jan, Raynard, See-See, Bazin, Ashley, Cremolini, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913844/
https://www.ncbi.nlm.nih.gov/pubmed/24337717
http://dx.doi.org/10.1007/s00520-013-2085-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913844/
https://www.ncbi.nlm.nih.gov/pubmed/24337717
http://dx.doi.org/10.1007/s00520-013-2085-z

Ejemplares similares